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Abstract 
The aim of this study was to evaluate the intestinal disposition of abiraterone acetate, an ester 
prodrug of the anticancer agent abiraterone. Stability of the prodrug and solubility and 
dissolution characteristics of both abiraterone and abiraterone acetate were monitored in vitro. 
Moreover, the in vivo intraluminal concentrations of abiraterone and abiraterone acetate upon 
intake of one tablet of 250 mg abiraterone acetate were assessed in healthy volunteers. The 
intestinal absorption resulting from the intraluminal behavior of the ester prodrug was 
determined using the rat in situ intestinal perfusion technique with mesenteric blood sampling. 
Simulated and aspirated human intestinal fluids of the fasted state were used as solvent 
systems. 
Upon incubation of abiraterone acetate in human intestinal fluids in vitro, rapid hydrolysis of 
the prodrug was observed, generating abiraterone concentrations largely exceeding the 
apparent solubility of abiraterone, suggesting the existence of intestinal supersaturation. These 
findings were confirmed in vivo, by intraluminal sampling of duodenal fluids upon oral intake 
of an abiraterone acetate tablet by healthy volunteers  
Rat in situ intestinal perfusion experiments performed with suspensions of abiraterone and 
abiraterone acetate in human intestinal fluids of the fasted state revealed significantly higher 
flux values upon perfusion with the prodrug than with abiraterone. Moreover, rat in situ 
intestinal perfusion with abiraterone acetate suspensions in simulated fluids of the fasted state 
in presence or absence of esterases demonstrated that increased hydrolytic activity of the 
perfusion medium was beneficial to the intestinal absorption of abiraterone.  
In conclusion, the rapid hydrolysis of abiraterone acetate in the intraluminal environment 
appears to result in fast and extensive generation of abiraterone supersaturation, creating a 
strong driving force for abiraterone absorption.  
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Introduction  
Hydrolytic enzymes including esterases are involved in the hydrolysis of a significant number 
of marketed prodrugs. Being ubiquitously present in the enterocytes, they pose an important 
limitation in the absorption of drugs carrying an ester bond [1]. In addition to intracellular 
hydrolysis, several studies report on the instability of ester prodrugs in human intestinal fluids 
[2–5]. In view of the labile nature of ester prodrugs, assessment of stability in intestinal fluids 
is crucial. Chemical and enzymatic intraluminal stability are often very important for the 
prodrug approach to be successful. Therefore, evaluating the stability of a prodrug in 
biorelevant fluids is a crucial step in prodrug development.  
Borde et al. proposed the use of dog intestinal fluids as an alternative to human intestinal 
fluids [2]. In the same study, the use of fasted state simulated intestinal fluids supplemented 
with pancreatin was also evaluated as a solvent system to determine ester prodrug stability; 
however, both in dog intestinal fluids and in the simulated fluids, degradation was found to be 
slower as compared to degradation in human intestinal fluids. 
The anticancer agent abiraterone is commercialized as abiraterone acetate (Zytiga®). The 
permeability of abiraterone acetate across Caco-2 monolayers is low and similar to the 
permeability of abiraterone. Moreover, poor aqueous solubility of the prodrug results in a 
BCS 4 classification of abiraterone acetate [7]. In accordance with these biopharmaceutical 
properties, the oral bioavailability of abiraterone upon intake of abiraterone acetate is low. As 
an up to 10-fold increase in abiraterone bioavailability was observed when administered with 
food, the systemic exposure upon oral intake should be lower than 10% [6]. Notwithstanding 
the significant positive effect of food on oral bioavailability, the ZYTIGA® label states that 
abiraterone acetate must be taken on an empty stomach with no food consumed for at least 
two hours before the dose and for at least one hour after the dose in order to reduce variability 
in absorption. The recommended dosing is 1000 mg once daily, and more than half of this 
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dose was demonstrated to be excreted unchanged via the faeces. Moreover, abiraterone, 
excreted via the faeces accounted for an additional 22% of the dose, administered in this mass 
balance study [8].  
The aim of this research was to gain insight into the mechanisms underlying the intestinal 
absorption of abiraterone. Solubility and stability experiments were performed in biorelevant 
fluids, including simulated intestinal fluids (FaSSIF) and aspirated human intestinal fluids 
(FaHIF) of the fasted state. Moreover, the in vivo intraluminal behavior of abiraterone acetate 
upon oral intake was studied in healthy volunteers. To gauge the repercussion of the 
intraluminal behavior of the ester prodrug on the intestinal absorption, the rat in situ intestinal 
perfusion technique with mesenteric blood sampling was selected as an appropriate absorption 
model.  
 
Materials and methods 
Chemicals 
Abiraterone, abiraterone acetate and their deuterated counterparts abiraterone-d4 and 
abiraterone acetate-d4 were kindly provided by Janssen Research & Development (Beerse, 
Belgium). VWR International (Leuven, Belgium) supplied methanol. Methyl tert-butyl ether 
(MTBE) was purchased from Merck (Overijse, Belgium). Esterase from porcine liver was 
obtained from Sigma Aldrich (St. Louis, MO). Acetonitrile and dimethylsulfoxide (DMSO) 
were purchased from Acros Organics (Geel, Belgium). Biorelevant (Surrey, UK) supplied 
simulated intestinal fluid (SIF) powder. Ketamine (Anesketin) and xylazin (Xyl-M 2%) were 
obtained from Eurovet (Heusden, Belgium) and VMD (Arendonk, Belgium), respectively. 
Stock solutions were prepared in DMSO. Water was purified with a Maxima system (Elga 
Ltd., High Wycombe Bucks, UK). 
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Media 
Fasted state simulated intestinal fluids (FaSSIF) were made according to the manufacturer’s 
protocol. Briefly, FaSSIF were prepared by dissolving SIF powder (2.24 mg/ml) in a blank 
FaSSIF phosphate buffer. Fasted state human intestinal fluids (FaHIF), used as a solvent 
system for the solubility measurements, the dissolution tests and the rat in situ intestinal 
perfusion experiments were collected from the duodenum of healthy volunteers in the fasted 
state (13 volunteers) according to the method described by Bevernage et al. (2011) [9]. The 
human intestinal fluids were collected every 15 min for up to 120 min from the duodenum 
(D2–D3) after the intake of 250 mL of water. One pooled sample was prepared by combining 
the aspirates from all volunteers. The pooled HIF were stored at -30°C until further use. 
Approval for the collection of FaHIF from volunteers was granted by the University Hospital 
Medical Ethics Commission of the KU Leuven. 
For the dissolution studies and the in situ intestinal perfusion experiments, the pH of FaSSIF 
was increased to 7.4, to better reflect the pH of the FaHIF pool. 
 
Solubility Measurements 
The apparent solubility of abiraterone and abiraterone acetate was determined in FaSSIF and 
in FaHIF using the shake flask method. All solubility experiments were performed in 
triplicate. Approximately 0.3 mg of abiraterone or abiraterone acetate (crystalline powder) 
was added to microcentrifuge tubes containing 0.3 mL of the above mentioned media and 
placed in a prewarmed shaking incubator [37°C at 175 rpm (KS 4000 i control incubator from 
Ika (Staufen, Germany))] for 24 h. In an effort to determine the time dependent changes in 
apparent solubility, samples were taken at 1h, 2h and 5h in addition to the 24h time point. The 
solid phase was separated from the dissolved part using centrifugation (15 min, 20.817g at 
37°C). The supernatant was immediately diluted 1/100 in MeOH:H2O (50:50). Before 
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analysis, the samples were further diluted to 1/1000 in MeOH:H2O (50:50) containing both 
abiraterone-d4 and abiraterone acetate-d4, used as internal standards at a final concentration 
of 5 nM.  
 
Dissolution tests 
Dissolution characteristics and supersaturation potential were investigated by adding 2 mg of 
abiraterone acetate or abiraterone to 2 ml of FaSSIF supplemented with esterases (20 U/ml) or 
to 2 ml of FaHIF. The experiments were performed in stirred medium maintained at 37°C. 
After adding the abiraterone acetate powder to the test medium, samples of 100 µl were taken 
at 5, 20, 40, 60 and 120 min and centrifuged (10 min, 21000 g, 37°C). The supernatant was 
immediately diluted 1/100 in MeOH:H2O (50:50). Before analysis, the samples were further 
diluted to 1/1000 in MeOH:H2O (50:50) containing both abiraterone-d4 and abiraterone 
acetate-d4 used as internal standards at a final concentration of 5 nM.  
 
Animals 
Purpose-bred, male Sprague-Dawley rats (Janvier, Le Genest Saint-Isle, France) were used 
for in situ intestinal perfusion experiments. The rats were housed according to the Belgian and 
European laws, guidelines and policies for animal experiments, housing and care in the 
Central Animal Facilities of the university. Approval for this project was granted by the 
Institutional Ethical Committee for Animal Experimentation. 
 
In situ intestinal perfusion 
Rats of approximately 350 g were anaesthetized using a mixture of ketamin (87.5 mg/kg) and 
xylazin (0.875 mg/kg). The right jugular vein was cannulated with a heparinized (50 IU/ml) 
polyethylene cannula (o.d. 1.02mm; Portex, Kent, UK) for blood supply from donor rats 
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during the perfusion experiment. A laparotomy was performed and a distal segment of the 
small intestine was isolated by inserting two glass cannulas (o.d. 4 mm, i.d. 3 mm) at the 
proximal and distal end of the segment. A mean intestinal segment radius of 0.2 cm was used 
in further calculations. Polyethylene tubing was connected to the inlet cannula and a perfusion 
pump (Minipuls3, Gilson, Middleton, USA) was placed between the perfusate reservoir and 
the inlet cannula. After removal of the intestinal content, the mesenteric vein draining the 
isolated part of the intestinal segment was cannulated using the top end (1 cm) of a catheter 
(Insyte-W® 0.7 x 19 mm; Beckton Dickinson, Salt Lake City, Utah) and the intestinal 
segment was preincubated with FaSSIF for 30 minutes at a perfusion flow rate of 1 ml/min. 
The cannula was secured with a knot and connected to a piece of silastic tubing (o.d. 
1.19 mm, i.d. 0.64 mm; Helix Medical, USA) for blood collection. During this 30 min 
preincubation period, a test tube containing a suspension of 3 mg of abiraterone or abiraterone 
acetate in 6 ml of FaSSIF, FaSSIF supplemented with esterase (20 U/ml) or FaHIF was placed 
in a water bath at 37°C. Magnetic stirrer bars provided mixing of the medium (400 rpm). 
After 30 min, the resulting suspension was used as perfusion medium. All in situ experiments 
were performed in the closed loop set-up to avoid excessive use of FaHIF and compound.  
The perfusion flow rate for all in situ experiments amounted to 1 ml/min. The blood from the 
mesenteric vein was continuously collected over 5-min intervals and the blood samples were 
immediately stored at -30°C prior to analysis. Donor blood was supplied via the jugular vein 
at a rate of 0.3 ml/min using a syringe pump (Pilot A2, Fresenius Vial, Grenoble, France) to 
maintain hemodynamic conditions. To verify the donor concentration, perfusate samples were 
taken every 10 min followed by a centrifugation step (5 min, 20817 g, 37°C). The supernatant 
was diluted 1/100 with methanol:water (50:50 v/v). Before analysis, the samples were further 
diluted to 1/1000 in MeOH:H2O (50:50) containing both abiraterone-d4 and abiraterone 
acetate-d4 as internal standards at a final concentration of 5 nM.  
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In vivo studies 
To evaluate the intraluminal behavior of abiraterone acetate in vivo, duodenal concentrations 
of abiraterone acetate and abiraterone were monitored in three healthy male volunteers (aged 
between 22 and 24 years). The procedure followed the tenets of the Declaration of Helsinki 
and was approved by the Committee of Medical Ethics of the University Hospitals Leuven, 
Belgium (ML9149) and the Federal Agency for Medicines and Health Products (EudraCT 
number 2013-005594-51). All volunteers provided written informed consent to participate in 
this study. After a fasting period of 12 h, a double-lumen polyvinyl catheter [Salem Sump 
Tube 14 Ch (external diameter 4.7 mm), Covidien, Dublin, Ireland] was introduced via the 
nose and positioned into the duodenum (D2/D3); positioning was checked by fluoroscopy. A 
tablet of 250 mg abiraterone acetate (ZYTIGA®, Janssen-Cilag International NV) was 
administered orally with 250 ml of water to the volunteers.  
During the experiment, volunteers were sitting in an upright position. Samples were taken 
every ten minutes in the first hour, and afterwards every fifteen minutes for up to four hours. 
The sampling volume was kept as small as possible (< 3 ml). The pH of the intestinal fluids 
was measured immediately after aspiration (Hamilton Knick Portamess Bonaduz, 
Switzerland). To determine the intraluminal concentrations of abiraterone and abiraterone 
acetate, 300 µl of the aspirated sample was immediately centrifuged (5 min, 20817 g, RT). 
The supernatant was diluted 1/100 in MeOH:H2O (50:50) containing both abiraterone-d4 and 
abiraterone acetate-d4 as internal standards at a final concentration of 5 nM. Additionally, 100 
µl of the aspirated sample was diluted 1/100 in MeOH:H2O (50:50) without a centrifugation 
step, to estimate the total amount of abiraterone and abiraterone acetate present in the 
intestinal fluids. Aspirated fluids and diluted samples were stored on ice during the in vivo 
experiments. Afterwards, 300 µl of the original aspirated sample was used to determine the 
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apparent solubility of abiraterone in the different intestinal samples. Solubility measurements 
were performed as described above (0.3 mg of abiraterone in 300 µl of sample).  
 
Analysis 
All samples were analyzed using an HPLC-MS/MS method. The detector was a TSQ 
Quantum with electron spray ionization applied in the positive polarity mode. The collision 
energy for abiraterone, abiraterone-d4, abiraterone acetate and abiraterone acetate-d4 was 51, 
56, 33 and 33 V, respectively. Mass transitions for abiraterone, abiraterone-d4, abiraterone 
acetate and abiraterone acetate-d4 were 350.2/156.1, 354.3/160.1, 392.3/332.2 and 
396.3/336.2, respectively. The following gradient of MeOH/H2O was run over a Kinetex C18 
column (50 x 3 mm, 1.7 µm; Phenomenex) at a flow rate of 350 µL/min: 40/60 (0 – 1 min), 
changed linearly to 95/5 (3 – 4.5 min), 40/60 (4.5 - 6 min). The injection volume was 10 µL 
and Xcalibur was used as the software program (Thermo-Electron, San Jose, USA).  
For the analysis of the mesenteric blood samples, abiraterone and abiraterone acetate were 
extracted from the blood before quantification by HPLC-MS/MS. After diluting 100 µl of 
blood in 400 µl of a mixture of acetonitrile:water (50:50), 100 µl of internal standard solution 
(solution of abiraterone-d4 and abiraterone acetate-d4 in acetonitrile:water (50:50), 5 nM) and 
200 µl of NaHCO3 (5%) were added. After extraction with 2 ml of methyl tert-butyl ether and 
centrifugation (2880 g, 5 min, 4°C), the organic layer was transferred to a clean test tube and 
evaporated to dryness under a gentle stream of air. The residue was dissolved in 150 µl of a 
solution of methanol:water (70:30 v/v), centrifuged (5 min, 20817 g, RT) and 10 µl of the 
supernatant was injected in the HPLC-MS/MS system.  
The calibration curves were linear from 500 nmol to 0.2 nmol. Precision and accuracy errors 
were below 10%.  
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Calculations 
The intestinal absorptive flux of abiraterone (abiraterone acetate was not detected in rat blood) 
was determined from the cumulative amount of compound appearing in the mesenteric blood 
according to equation (1): 
        (1) 
 
where dQ/dt is the amount of drug appearing in the mesenteric blood over time and A is the 
surface area of the perfused cylindrical intestinal segment. 
 
Results and discussion 
The purpose of this study was to gain insight into the intraluminal behavior and intestinal 
absorption of abiraterone acetate, an ester prodrug of the anticancer agent abiraterone. Due to 
its poor aqueous solubility and intestinal permeability, abiraterone acetate has been classified 
as BCS class IV [7]. As, according to the summary of product characteristics of ZYTIGA®, 
the prodrug is to be taken in fasted state conditions, solubility studies, dissolution tests and 
absorption experiments were performed in intestinal media relevant for the fasted state. 
Aspirated human intestinal fluids of the fasted state (FaHIF) were used as key reference 
solvent systems and results were compared to those obtained with the simulated fluids of the 
fasted state. In view of the reported literature on prodrug instability in intestinal juices, 
stability of abiraterone acetate and formation of abiraterone were carefully monitored 
throughout the experiments. 
In vivo intraluminal concentrations of abiraterone acetate and abiraterone upon intake of one 
tablet of 250 mg abiraterone acetate were determined in healthy volunteers in order to 
evaluate the relevance of the in vitro solubility and dissolution experiments. In addition, in 
situ intestinal perfusion with mesenteric sampling in rats was selected as the most appropriate 
𝐹𝑙𝑢𝑥 =
dQ
dt. A
 
13 
 
absorption model to evaluate the intestinal uptake of abiraterone and its ester prodrug from 
biorelevant perfusion media.  
 
Solubility measurements 
Abiraterone acetate is practically insoluble in aqueous media and very slightly soluble in 0.1N 
HCl [6]. Nevertheless, over the past decade, it has become abundantly clear that, in order to 
estimate intraluminal concentrations, solubility studies should be performed in media that are 
relevant for the in vivo intestinal environment [10]. In the present study, apparent solubility 
was determined in simulated (FaSSIF) and aspirated (FaHIF) intestinal fluids of the fasted 
state. The composition of the media used and their solubilizing capacity for abiraterone and 
abiraterone acetate are presented in Table 1. 
Upon 5 h of incubation, the solubilities of abiraterone and abiraterone acetate in FaSSIF were 
12.7 ± 4.2 and 64.6 ± 5.2 µM, respectively. In FaHIF, the solubility of abiraterone acetate was 
37.4 ± 0.3 µM.; however, generation of abiraterone upon incubation of the prodrug was 
observed, suggesting degradation of abiraterone acetate in human intestinal fluids. 
Interestingly, the abiraterone concentrations reached upon prodrug incubation (23.9 ± 0.9 
µM), strongly exceeded the solubility values obtained when incubating abiraterone in FaHIF 
(3.1 ± 0.2 µM).  
Due to the instable nature of the prodrug in human intestinal fluids, and the relatively late 
sampling time points as compared to intestinal transit times, the in vivo relevance of the 
apparent solubility values of abiraterone and abiraterone acetate may be limited. To further 
characterize the intraluminal behavior of abiraterone acetate, dissolution tests and in vivo 
experiments were performed. 
 
14 
 
Stability and dissolution tests 
Instability in intestinal fluids has been observed for several other ester prodrugs and is 
generally regarded as disadvantageous to the overall prodrug approach [2,11]. A more 
thorough evaluation of the concentration profiles of abiraterone and abiraterone acetate upon 
prodrug incubation in FaHIF during the solubility studies indicates that the concentrations of 
abiraterone generated by prodrug hydrolysis upon 1, 2 and 5 hours of incubation were 
significantly higher than the solubility of abiraterone determined by incubation of abiraterone 
(Figure 1). Apparently, the relatively fast dissolution and subsequent degradation of 
abiraterone acetate in FaHIF triggers rapid and extensive formation of abiraterone. In 
contrast, the dissolution of abiraterone appears to be very slow as compared to 
dissolution of the prodrug. 
 
To further explore the observed behavior of abiraterone acetate in FaHIF, the prodrug was 
incubated in dissolution vessels for a shorter time span. Powder of the prodrug or abiraterone 
was added to FaHIF or FaSSIF supplemented with esterases (20 U/ml) and incubated for 2h 
with regular sampling.  
Incubation of abiraterone acetate in human intestinal fluids of the fasted state confirmed the 
observations made during the solubility studies: prodrug incubation resulted in rapid 
degradation, generating abiraterone concentrations exceeding its apparent solubility. The 
concentration-time profile of abiraterone peaked at 20 minutes, reaching 80 µM, which is 
about fourfold higher than the apparent solubility of abiraterone determined after 24h (Figure 
2a). Moreover, when comparing the in vitro behavior of the prodrug and abiraterone in 
FaHIF, the concentration of abiraterone generated upon prodrug incubation significantly rises 
above the concentrations obtained upon abiraterone incubation. At its peak concentration after 
20 minutes of incubation, prodrug-induced abiraterone concentrations are more than 11-fold 
higher than concentrations reached upon abiraterone incubation in FaHIF.  
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In contrast to its fast degradation in FaHIF, abiraterone acetate was found to be stable in 
FaSSIF. In an effort to increase the relevance of using FaSSIF as a solvent system to assess 
the intraluminal behavior of ester prodrugs, esterases (20 U/ml) were added to the simulated 
intestinal fluids and the pH was set at 7.4, which is similar to the pH measured for the 
aspirated human intestinal fluids. In agreement with the data obtained in FaHIF, considerable 
formation of abiraterone was observed upon incubation of the prodrug, strongly exceeding the 
abiraterone concentrations measured upon abiraterone incubation (Figure 2b). As compared to 
the human intestinal fluids, prodrug degradation in the simulated fluids seems to be slower 
and abiraterone concentrations peak at 60 minutes of incubation. This is probably due to a 
higher hydrolytic activity in the human intestinal fluids. Nevertheless, from a qualitative point 
of view, the behavior of prodrug and abiraterone upon incubation in simulated and aspirated 
intestinal fluids is similar.  
It appears that the seemingly non-productive hydrolysis of abiraterone acetate results in 
periods of intraluminal abiraterone supersaturation. Given the reported similar permeability of 
abiraterone and abiraterone acetate across Caco-2 monolayers, instability of the ester prodrug 
in the intraluminal environment may surprisingly be beneficial to the overall intestinal 
disposition of abiraterone [7].  
 
In vivo intraluminal behavior of abiraterone acetate 
To estimate the in vivo relevance of the observed in vitro behavior of abiraterone acetate, 
intraluminal sampling was performed from the duodenum of healthy volunteers after intake of 
a tablet of abiraterone acetate (ZYTIGA®, 250 mg). The tablet was administered together with 
250 ml of water and was taken on an empty stomach. Samples were taken over a period of 4h.  
Over the entire sampling period, only marginal concentrations of abiraterone acetate could be 
measured in the aspirated samples. In contrast, periods of high abiraterone concentrations 
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were observed, clearly indicating that abiraterone is the major species in solution in the 
intraluminal environment (Figure 3a). The abiraterone concentrations observed in vivo were 
even higher than the concentrations that were generated during the in vitro experiments. This 
may be attributed to the fact that in vivo, dissolution may already occur in the stomach, in 
which the acidic pH is beneficial for the solubility of the weak base abiraterone acetate. When 
the total quantity of abiraterone and abiraterone acetate present in the aspirates was 
determined, however, significant amounts of the prodrug were detected, indicating that 
abiraterone acetate predominantly resides in the duodenum as undissolved powder (Figure 
3b). These in vivo observations are in good agreement with the high recovery of abiraterone 
acetate in the faeces, which was observed in a mass balance study in healthy volunteers [8]. 
Moreover, as is clear from our data, the fraction of abiraterone acetate that goes into solution 
is rapidly converted to abiraterone. For abiraterone, the total amounts were much more in line 
with the solubilized fraction, indicating that, at the time of sampling, minor precipitation of 
abiraterone occurred at the sampling site (data not shown). This finding also suggests that 
supersaturation of abiraterone in vivo is more stable than in vitro, where precipitation of 
abiraterone was observed already after 20 min of incubation in fasted state human intestinal 
fluids (Figure 2a). This can be explained by the fact that in vivo, the precipitation rate might 
be reduced by the presence of an absorptive sink [12]. 
The maximum concentrations of abiraterone in the intraluminal samples were observed within 
the first hour after intake of the tablet, indicating a relatively fast gastrointestinal transfer. For 
all three volunteers, one major abiraterone peak was observed in the concentration-time 
profile. 
Comparison of duodenal concentrations and solubility values determined for abiraterone in 
the aspirated intestinal samples suggests the existence of periods of intraluminal 
supersaturation of abiraterone. Especially at sampling times when peak concentrations were 
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observed, the abiraterone concentration in solution strongly surmounted the solubility values 
(Figure 3c). The average abiraterone solubility in all individually aspirated samples (18.6 µM) 
was very similar to the abiraterone solubility determined in the FaHIF pool (16.5 µM), which 
was used in the in vitro and in situ experiments. This finding indicates that, with respect to 
solubility, the FaHIF pool was representative for the intraluminal samples obtained after 
administration of the abiraterone acetate tablet to healthy volunteers.  
Overall, the in vivo observations confirm the in vitro data and indicate that the process of 
rapid prodrug dissolution and subsequent degradation indeed occurs in vivo and can generate 
intraluminal supersaturation. 
 
In situ evaluation of abiraterone absorption 
Based on the observed in vitro and in vivo behavior of abiraterone acetate, the intraluminal 
degradation of the prodrug will be a critical factor affecting the intestinal absorption of 
abiraterone. To evaluate the impact of this instability on the intestinal absorption of 
abiraterone, in situ intestinal perfusion experiments with mesenteric blood sampling were 
performed in rats. Simulated and aspirated human intestinal fluids of the fasted state 
containing abiraterone or abiraterone acetate powder were used as perfusion media to assess 
the value of the prodrug approach. In all experimental conditions, an excess of powder was 
added to the perfusion media, and, consequently, intestinal perfusions were performed with 
suspensions. This was done in accordance with the presence of non-dissolved abiraterone 
acetate residing in the intraluminal environment, as observed in the in vivo experiments 
performed in this study (Figure 3b), as well as the mass balance of abiraterone, reported by 
Acharya et al. [8]. 
Upon perfusion with abiraterone suspensions in human intestinal fluids of the fasted state, low 
abiraterone concentrations were observed in the perfusion solution. This is in good agreement 
with the results obtained from the dissolution studies with abiraterone in FaHIF. 
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Consequently, the abiraterone concentrations measured in the mesenteric blood were 
relatively low. When intestinal perfusions were performed with suspensions containing the 
prodrug powder, however, the high concentrations of abiraterone generated by the instability 
of the ester prodrug, resulted in an important increase in abiraterone flux towards the 
mesenteric blood (Figure 4a). Not surprisingly, no abiraterone acetate was detected in the 
mesenteric blood, as only a low proportion of prodrug was present in the perfusion medium, 
and the prodrug is also hydrolyzed in the enterocytes.  
The use of simulated fluids of the fasted state in presence or absence of esterases, allows an 
estimation of the effect of the hydrolytic activity of the medium on the intestinal absorption of 
abiraterone. When perfusing abiraterone acetate suspensions in FaSSIF, only the prodrug 
could be measured in the perfusion medium, which was anticipated in view of the stability of 
the prodrug in these simulated intestinal fluids. In contrast, when using FaSSIF supplemented 
with esterases, both abiraterone acetate and abiraterone were present in the perfusion medium 
and abiraterone concentrations exceeded prodrug concentrations on average by 5-fold during 
the perfusion experiments. Moreover, the cumulative concentration of abiraterone and 
abiraterone acetate in the perfusion solution was higher in FaSSIF supplemented with 
esterases as compared to plain FaSSIF. Accordingly, given the fact that abiraterone and 
abiraterone acetate exhibit similar permeability values, the resulting flux values of abiraterone 
towards the mesenteric blood when perfusing FaSSIF supplemented with esterases 
surmounted the abiraterone flux upon perfusion of prodrug in FaSSIF by 2-fold (Figure 4b). 
These findings unexpectedly indicate that adding hydrolase activity to the perfusion medium 
increases the intestinal absorption of abiraterone when supplemented as an acetate ester 
prodrug. Consistent with the observations in FaHIF, the absorptive flux values obtained upon 
perfusing abiraterone suspensions in simulated intestinal fluids of the fasted state were 
significantly lower compared to flux values obtained when perfusing the prodrug in presence 
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or absence of esterases. Moreover, both perfusate concentrations of abiraterone and absorptive 
flux values were very similar in simulated and aspirated intestinal fluids when perfusing 
abiraterone suspensions. 
 
Conclusion 
The results of this study demonstrate that the success of the prodrug cannot be explained by 
an increased intestinal absorption and subsequent post-absorptive degradation of abiraterone 
acetate, which is most commonly the aim when applying a prodrug approach [11]. In contrast, 
based on the in vitro, in vivo and in situ results presented here, it appears that fast dissolution 
and subsequent immediate degradation of the prodrug is the underlying mechanism justifying 
the use of the prodrug over abiraterone. Based on the apparent solubility values for 
abiraterone in fasted state intestinal fluids, this mechanism may induce periods of intraluminal 
supersaturation, creating a strong driving force for intestinal absorption. 
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Table 1:Individual bile salt and lecithin concentrations in FaSSIF and FaHIF and the solubility (5h) of abiraterone and abiraterone acetate in these media. 
Medium 
Bile Salt Concentration (µM) Lecithin concentration  
(µM) 
Abiraterone  
solubility (µM) 
Abiraterone acetate 
solubility (µM) TUDC TCDC TDC GUDC GCDC GDC GC TC Total 
FaHIF 8 289 178 25 616 507 1005 374 3002 986 3.1 ± 0.2 37.4 ± 0.3 
FaSSIF 
       
3000 3000 750 12.7 ± 4.2 64.6 ± 5.2 
TUDC: tauroursodeoxycholate, TCDC: taurochenodeoxycholate, TDC: taurodeoxycholate, GUDC: glycoursodeoxycholate, GCDC: glycochenodeoxycholate, GDC: glycodeoxycholate, GC: 
glycocholate, TC: taurocholate 
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Legend for figures 
Figure 1: Time dependent apparent solubility of abiraterone in FaHIF upon incubation of 
abiraterone (black bars) and abiraterone acetate (white bars) powder. Bars represent the mean 
+ SD (n=3). 
 
Figure 2: Concentration-time profiles of abiraterone upon dissolution of abiraterone acetate 
(□) and abiraterone (▲) powder in FaHIF (2a) and FaSSIF complemented with esterases (2b). 
Symbols represent the mean ± SD (n=3). 
 
Figure 3: a) Duodenal concentrations of abiraterone (open symbols) and abiraterone acetate 
(closed symbols) over time b) Total amount (open symbols) and duodenal concentration 
(closed symbols) of abiraterone acetate over time. Values for the total amount are 
expressed as concentrations that would be measured if the total amount of abiraterone 
acetate were in solution in the intraluminal samples. c) Duodenal concentrations (open 
symbols) and solubility (closed symbols) of abiraterone over time. Symbols represent the 
mean ± SEM (n=3). 
 
Figure 4: Absorptive flux values of abiraterone over time in aspirated (4a) and simulated (4b) 
intestinal fluids of the fasted state. 4a: Squares and triangles represent absorptive flux values 
upon perfusions in FaHIF starting from abiraterone acetate and abiraterone suspensions, 
respectively. 4b: Triangles and diamonds represent absorptive flux values upon perfusions in 
FaSSIF starting from abiraterone and abiraterone acetate suspensions, respectively. Squares 
represent absorptive flux values upon perfusions in FaSSIF supplemented with esterases 
starting from abiraterone acetate suspensions. Symbols represent the mean ± SD (n=3). 
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Figure 4 
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